DXB 4.44% 21.5¢ dimerix limited

Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-4

  1. 141 Posts.
    lightbulb Created with Sketch. 30
    DIMERIX ANNOUNCES POSITIVE TOP-LINE RESULTS IN
    PHASE 2a CLINICAL STUDY OF DMX-200 IN FSGS
    Highlights
    • Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients
    • DMX-200 was found to be generally safe and well-tolerated in FSGS patients
    • 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo
    • A 29% reduction in proteinuria was observed across all patients receiving DMX-200 compared to
    placebo
    • 29% of patients achieved a >40% reduction in proteinuria on DMX-200 compared to placebo
    • Multiple patients from both FSGS and diabetic kidney disease studies continue on DMX-200 via
    TGA Special Access Scheme
    • Statistically powered Phase 2 study in diabetic kidney disease results due in 4 - 6 weeks
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
21.5¢
Change
-0.010(4.44%)
Mkt cap ! $42.51M
Open High Low Value Volume
23.0¢ 23.0¢ 21.5¢ $415.2K 1.848M

Buyers (Bids)

No. Vol. Price($)
9 647433 21.5¢
 

Sellers (Offers)

Price($) Vol. No.
22.5¢ 20000 1
View Market Depth
Last trade - 16.10pm 24/09/2020 (20 minute delay) ?
(live)
Last
22.0¢
  Change
-0.010 ( 2.22 %)
Open High Low Volume
22.5¢ 23.0¢ 22.0¢ 1046886
Last updated 15.58pm 24/09/2020 (live) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.